Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by rgonlyfactsplson Sep 11, 2013 7:41am
345 Views
Post# 21731766

Dear AstraZeneca... pls plan a shopping trip to Belleville asap...

Dear AstraZeneca... pls plan a shopping trip to Belleville asap...

Dear BNC...are you aware AstraZeneca is shopping and paying "fair" fees/payments?...

AstraZeneca pays $50 mln for rights to Merck cancer drug

Sept 11 | Wed Sep 11, 2013 6:52am EDT

Sept 11 (Reuters) - Merck & Co Inc has licensed its experimental cancer drug to AstraZeneca Plc for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.
Under the terms of the agreement, Merck, the No. 2 U.S. drugmaker, will also be eligible to receive future payments related to development and regulatory milestones, as well as tiered royalties.
The drug, MK-1775, is currently in mid-stage trials in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer.
https://www.reuters.com/article/2013/09/11/merck-idUSL3N0H72CV20130911

https://www.pharmatimes.com/Article/13-09-11/AZ_pays_50_million_upfront_for_Merck_Co_cancer_drug.aspx

https://uk.reuters.com/article/2013/08/26/uk-astrazeneca-amplimmune-idUKBRE97P07W20130826

<< Previous
Bullboard Posts
Next >>